Pasithea Therapeutics Corp.
No SEC Form 4 filings for $KTTA in the last 30 days.
See all $KTTA insider activity →Pasithea reported Phase 1 data for PAS-004, showing stable disease in 4 advanced cancer patients, with no serious adverse events. The company noted no dose-limiting toxicities and supports daily dosing. The data is preliminary and requires further Phase 2 studies for validation.
Pasithea Therapeutics Corp. (KTTA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 9, 2026, the Company held its Annual Meeting. The stockholders of the Company acted upon the following three proposals at the Annual Meeting: (1) the election of two Class III directors; (2) the ratifica
Pasithea Therapeutics Corp. (KTTA) disclosed in an SEC Schedule 13G/A that Vivo Opportunity entities hold just under 10% of its common stock. Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. each report 9.99% beneficial ownership, including common shares and pre-funded warrants. The filing cites 33,414,448 shares outstanding as of May 13, 2026.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning KTTA (Pasithea Therapeutics Corp.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent KTTA coverage spans financial news, corporate actions and insider activity.
Positive early‑stage data may lift sentiment and support a price uptick, but limited patient numbers keep impact modest.
Potential dilution and share price adjustment from the approved reverse split; governance changes may affect future strategy.
A near-10% beneficial ownership position with warrant-linked issuance and a 9.99% cap can affect control dynamics and future dilution expectations.
A 10% owner’s indirect open-market purchase is a modest, sentiment-relevant signal but not a fundamental catalyst by itself.
Orphan designation improves regulatory and commercial optionality for PAS-004 in ALS, potentially strengthening investor expectations for future trial/approval pathways.
AlphAI scores every news story that mentions KTTA with an AI model for sentiment and relevance, and aggregates insider trades from Pasithea Therapeutics Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pasithea reported Phase 1 data for PAS-004, showing stable disease in 4 advanced cancer patients, with no serious adverse events. The company noted no dose-limiting toxicities and supports daily dosing. The data is preliminary and requires further Phase 2 studies for validation.
1 min readPasithea Therapeutics Corp. (KTTA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 9, 2026, the Company held its Annual Meeting. The stockholders of the Company acted upon the following three proposals at the Annual Meeting: (1) the election of two Class III directors; (2) the ratifica
1 min readPasithea Therapeutics Corp. (KTTA) disclosed in an SEC Schedule 13G/A that Vivo Opportunity entities hold just under 10% of its common stock. Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. each report 9.99% beneficial ownership, including common shares and pre-funded warrants. The filing cites 33,414,448 shares outstanding as of May 13, 2026.
4 min readCoastlands Capital LP purchased 100,000 indirectly-held shares of Pasithea Therapeutics Corp. (KTTA) at $0.53 on 2026-06-17.
2 min readPasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.
3 min readThis page provides a comprehensive resource for investors and traders to access Pasithea Therapeutics (KTTA) SEC filings, including annual, quarterly, and material event reports, alongside insider trading forms. Each filing is accompanied by an AI-generated summary, sentiment and impact scores, and end-of-day stock performance data. The platform aims to simplify access to critical regulatory disclosures with analytical insights and historical market reactions.
3 min readMIAMI, Nov. 28, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. ( "Pasithea" or the "Company" ) ( Nasdaq: KTTA. KTTAW ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated ...
3 min readPasithea Therapeutics Corp ( NASDAQ:KTTA ) shares are trading sharply higher Wednesday morning after a string of upbeat updates on its lead drug candidate, PAS-004, capped by a new $1 million grant from the ALS Association. Here's what investors need to know. KTTA is among today's top ...
2 min read-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable disease and ...
3 min read-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.
3 min read
